rating. In a surprising move, Pfizer named longtime veteran Ian Read to the CEO post in December 2010, abruptly replacing Jeffrey Kindler . We believe the earlier-than-anticipated departure of Kindler was largely due to personal reasons and don't believe
Aug 8 (Reuters) - Jeff Kindler , the former chief executive of Pfizer Inc, has joined venture capital firm Lux Capital as a partner, Lux said in a statement, where he will help scout for healthcare...
surprise, but you are comfortable with Read at the helm? Conover : Yes, you know, it was a surprise. The previous CEO, Jeff Kindler , I thought was doing a fine job. I think Read is going to follow in his footsteps in the sense that I think we'll see
In a surprising move, Pfizer PFE appointed Ian Read as its new CEO replacing Jeff Kindler , who decided to retire for personal reasons. While Kindler's abrupt department raises a few red flags, we don't expect any
the CEOs at big pharma firms, Frazier lacks much laboratory experience. Instead, as is the case with Pfizer's PFE CEO Jeff Kindler , Frazier brings an excellent legal background, as he was largely responsible for the company's successful Vioxx defense
to review Pfizer s third quarter 2010 performance, 2010 financial guidance, and 2012 long range targets. I m here with Jeff Kindler , Frank D'Amelio, Ian Read and other members of our leadership team. The financial charts that will be presented on this
review Pfizer's Second Quarter 2010 Performance , 2010 financial guidance , and 2012 long - range target . I'm here with Jeff Kindler , Frank D'Amelio , Ian Read and other members of our leadership team . Thanks , Chuck and good morning everyone . I will
today to review our first quarter 2010 performance , 2010 financial guidance and 2012 long range targets . I am here with Jeff Kindler , Frank D'Amelio , Ian Read and other members of our leadership team . The financial charts that will be presented on this
Pfizer PFE released an update on its pipeline Monday. In keeping with CEO Jeff Kindler 's efforts to provide more transparency, the company issued a full list of its early-stage products in development. We view
bring in new talent from outside the company to fill these posts. We think these departures are probably part of new CEO Jeffrey Kindler 's plan to overhaul the company. Both executives had been with Pfizer for more than 20 years, although Levin had only